Oncolytics is a biotechnology company developing REOLYSIN®, an immuno-oncology viral-agent, as a potential treatment for a variety of tumor types. The Company is listed on the Toronto Stock Exchange (TSX:ONC) and quoted on the OTCQX® Best Market (OTCQX:ONCYF). In addition to the information available on this site, investors can access the Company’s regulatory filings on the SEDAR website at www.sedar.com and on the EDGAR website at www.sec.gov.
|TSX: ONC||$ CAD|
|OTCQX: ONCYF||$ USD|
Access our quarterly and year-end financial statements, MD&A, information circulars and annual reports.
Oncolytics Biotech Inc. believes in a transparent and forward-facing approach to business.
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More